ubidecarenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4607 303-98-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • neuquinon
  • ubidecarenone
  • Vitamin Q
prevents hemorrhagic state
  • Molecular weight: 863.37
  • Formula: C59H90O4
  • CLOGP: 12
  • LIPINSKI: 2
  • HAC: 4
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -6.65
  • ROTB: 31

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasticity 363.28 14.56 157 17384 17027 50570556
Ear pain 314.16 14.56 166 17375 28117 50559466
Night sweats 292.85 14.56 168 17373 33406 50554177
Respiratory disorder 285.30 14.56 161 17380 31026 50556557
Body temperature increased 279.17 14.56 159 17382 31182 50556401
Insomnia 150.43 14.56 239 17302 174626 50412957
Sinusitis 146.54 14.56 233 17308 170325 50417258
Back pain 141.09 14.56 264 17277 219766 50367817
Peripheral swelling 139.46 14.56 253 17288 205683 50381900
Urticaria 136.89 14.56 195 17346 129366 50458217
Lower respiratory tract infection 118.20 14.56 155 17386 95046 50492537
Asthenia 116.10 14.56 305 17236 318737 50268846
Pruritus 110.25 14.56 278 17263 283290 50304293
Abdominal pain upper 95.59 14.56 186 17355 159123 50428460
Diarrhoea 71.08 14.56 395 17146 588081 49999502
Toxicity to various agents 58.14 14.56 4 17537 212495 50375088
Rash 57.65 14.56 301 17240 437170 50150413
Joint swelling 57.35 14.56 201 17340 245085 50342498
Headache 56.43 14.56 333 17208 506202 50081381
Pain 37.36 14.56 334 17207 578569 50009014
Maternal exposure during pregnancy 31.97 14.56 8 17533 159770 50427813
Fatigue 30.84 14.56 377 17164 707224 49880359
General physical health deterioration 30.78 14.56 6 17535 142428 50445155
Acute kidney injury 30.31 14.56 21 17520 228037 50359546
Infusion related reaction 29.40 14.56 11 17530 169546 50418037
Exposure during pregnancy 28.59 14.56 4 17537 121011 50466572
Pemphigus 28.32 14.56 4 17537 120162 50467421
Systemic lupus erythematosus 28.21 14.56 7 17534 140615 50446968
Treatment failure 27.32 14.56 7 17534 137630 50449953
Incorrect route of product administration 25.64 14.56 32 17509 18634 50568949
Full blood count decreased 25.55 14.56 35 17506 22311 50565272
Hand deformity 22.11 14.56 4 17537 100195 50487388
Vomiting 20.63 14.56 247 17294 460511 50127072
Muscle spasms 20.46 14.56 92 17449 125461 50462122
Death 19.11 14.56 54 17487 325325 50262258
Drug ineffective 18.71 14.56 188 17353 819145 49768438
Pericarditis 17.67 14.56 3 17538 78686 50508897
Glossodynia 17.65 14.56 9 17532 115560 50472023
Low density lipoprotein increased 17.51 14.56 15 17526 5631 50581952
Mitochondrial DNA deletion 16.51 14.56 3 17538 10 50587573
Myalgia 15.88 14.56 85 17456 124234 50463349
Product dose omission issue 14.95 14.56 112 17429 183726 50403857
Overdose 14.88 14.56 8 17533 99719 50487864
Hypokalaemia 14.76 14.56 6 17535 87986 50499597

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fatigue 76.54 15.20 230 8198 316591 29249508
Blindness cortical 41.00 15.20 11 8417 334 29565765
Asthenia 30.80 15.20 132 8296 215118 29350981
Full blood count decreased 23.86 15.20 26 8402 15966 29550133
Constipation 22.86 15.20 78 8350 114082 29452017
Dysgeusia 22.55 15.20 30 8398 22644 29543455
Toxicity to various agents 22.04 15.20 11 8417 173650 29392449
Abdominal discomfort 21.20 15.20 44 8384 47859 29518240
Peripheral swelling 18.85 15.20 50 8378 63689 29502410
Protein total increased 18.68 15.20 10 8418 2108 29563991
Diarrhoea 17.74 15.20 158 8270 332540 29233559
Dizziness 17.61 15.20 103 8325 189581 29376518
Plasma cell myeloma 17.50 15.20 35 8393 37080 29529019
Myalgia 16.07 15.20 52 8376 73967 29492132
Application site inflammation 15.58 15.20 4 8424 102 29565997
Adverse drug reaction 15.57 15.20 26 8402 23994 29542105
Back pain 15.56 15.20 64 8364 102220 29463879
Muscle spasms 15.30 15.20 47 8381 65035 29501064

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasticity 152.15 12.92 82 19360 16587 64462703
Ear pain 140.48 12.92 90 19352 25046 64454244
Night sweats 128.60 12.92 98 19344 35948 64443342
Body temperature increased 99.59 12.92 85 19357 36581 64442709
Respiratory disorder 98.67 12.92 84 19358 36027 64443263
Back pain 86.17 12.92 215 19227 249956 64229334
Insomnia 75.55 12.92 177 19265 197659 64281631
Peripheral swelling 75.43 12.92 183 19259 208970 64270320
Asthenia 72.12 12.92 287 19155 427757 64051533
Toxicity to various agents 67.01 12.92 14 19428 363499 64115791
Fatigue 60.74 12.92 409 19033 748321 63730969
Sinusitis 58.35 12.92 133 19309 145795 64333495
Diarrhoea 47.72 12.92 376 19066 722328 63756962
Pruritus 47.41 12.92 203 19239 312197 64167093
Completed suicide 47.21 12.92 6 19436 224408 64254882
Abdominal pain upper 40.15 12.92 130 19312 174900 64304390
Urticaria 39.92 12.92 116 19326 147201 64332089
General physical health deterioration 35.38 12.92 9 19433 204416 64274874
Lower respiratory tract infection 35.34 12.92 84 19358 94530 64384760
Myalgia 32.98 12.92 114 19328 158503 64320787
Headache 31.34 12.92 269 19173 529198 63950092
Blindness cortical 31.09 12.92 11 19431 802 64478488
Pain 30.59 12.92 277 19165 553234 63926056
Rash 30.36 12.92 239 19203 458310 64020980
Drug abuse 29.17 12.92 3 19439 132371 64346919
Overdose 27.65 12.92 7 19435 159559 64319731
Acute kidney injury 27.55 12.92 59 19383 449181 64030109
Muscle spasms 24.79 12.92 96 19346 140927 64338363
Full blood count decreased 24.35 12.92 32 19410 22550 64456740
Feeling abnormal 24.35 12.92 92 19350 133510 64345780
Drug interaction 20.20 12.92 50 19392 362033 64117257
Dysgeusia 20.02 12.92 44 19398 47003 64432287
Joint swelling 19.97 12.92 122 19320 215260 64264030
Pain in extremity 17.35 12.92 153 19289 302932 64176358
Low density lipoprotein increased 17.14 12.92 16 19426 7724 64471566
Treatment failure 16.92 12.92 7 19435 116809 64362481
Coma 16.90 12.92 3 19439 87612 64391678
Mitochondrial DNA deletion 16.50 12.92 3 19439 12 64479278
Incorrect route of product administration 16.39 12.92 27 19415 23271 64456019
Product dose omission issue 16.00 12.92 107 19335 194640 64284650
Dizziness 15.18 12.92 197 19245 429966 64049324
C-reactive protein increased 14.90 12.92 5 19437 94904 64384386
Flatulence 14.77 12.92 33 19409 35633 64443657
Infusion related reaction 14.41 12.92 17 19425 164450 64314840
White blood cell count decreased 14.36 12.92 89 19353 157748 64321542
Cardio-respiratory arrest 14.09 12.92 6 19436 98387 64380903
Febrile neutropenia 13.82 12.92 22 19420 187635 64291655
Intentional overdose 13.67 12.92 5 19437 89939 64389351
Therapy cessation 13.39 12.92 30 19412 32459 64446831
Hyponatraemia 13.35 12.92 15 19427 148324 64330966

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EB09 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Other cardiac preparations
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:173084 ferroptosis inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Congestive heart failure indication 42343007 DOID:6000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01065 KEGG_DRUG
4021303 VUID
N0000148739 NUI
4021303 VANDF
CHEBI:46245 CHEBI
U10 PDB_CHEM_ID
CHEMBL454801 ChEMBL_ID
C010524 MESH_SUPPLEMENTAL_RECORD_UI
3463 INN_ID
DB09270 DRUGBANK_ID
EJ27X76M46 UNII
5281915 PUBCHEM_CID
21406 RXNORM
15490 MMSL
194138 MMSL
233517 MMSL
270084 MMSL
33141 MMSL
33199 MMSL
33200 MMSL
37841 MMSL
46285 MMSL
74202 MMSL
d04523 MMSL
003911 NDDF
012958 NDDF
412129003 SNOMEDCT_US
412130008 SNOMEDCT_US
C0041536 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
IQQU Acne Serum HUMAN OTC DRUG LABEL 3 50403-226 LOTION 0.00 g TOPICAL UNAPPROVED DRUG OTHER 9 sections
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 65121-301 CAPSULE, GELATIN COATED 50 mg ORAL unapproved drug other 5 sections
Vita-Rx Diabetic Vitamin HUMAN PRESCRIPTION DRUG LABEL 14 69677-050 CAPSULE, GELATIN COATED 50 mg ORAL unapproved drug other 5 sections
Zyrexal HUMAN PRESCRIPTION DRUG LABEL 8 72380-915 TABLET 75 mg ORAL unapproved drug other 8 sections